OptimizeRx Corporation reports developments in healthcare technology for life sciences marketing, with updates centered on tools that connect pharmaceutical brands with healthcare professionals and patients. The company’s platform uses EHR-based access, omnichannel activation, the Dynamic Audience Activation Platform, and Micro-Neighborhood audiences to support HCP and direct-to-consumer engagement.
Recurring OptimizeRx news includes product and network launches, programmatic access to EHR advertising, privacy-safe identity resolution collaborations, quarterly and annual results, debt and share-repurchase actions, and board or leadership changes. Coverage also reflects the company’s focus on privacy-compliant audience targeting and campaign measurement across healthcare marketing channels.
OptimizeRx Corp. (Nasdaq: OPRX) announced record preliminary financial results for the fourth quarter and full year ended December 31, 2020. The company expects fourth-quarter revenue to reach approximately $16 million, a 117% increase year-over-year, alongside positive GAAP net income. For the full year, revenue is projected at $43 million, up 75%. Strong growth is attributed to increased demand for digital health solutions from life science companies. OptimizeRx aims for continued expansion, reporting a robust sales pipeline of $170 million heading into 2021.
OptimizeRx Corp. (Nasdaq: OPRX), a leader in digital health solutions, announced its upcoming presentation at the B. Riley Securities 2021 Vision Day Conference on January 28, 2021, at 1:30 p.m. Eastern time. CEO William Febbo will discuss the company's expansive digital health platform, which connects life science companies with patients' care journeys, facilitating medication affordability and adherence. The event will feature a live webcast and is expected to address OptimizeRx's growth opportunities and new digital health solutions.
OptimizeRx Corp. (Nasdaq: OPRX) has been invited to present at the H.C. Wainwright BioConnect Conference, taking place virtually from January 11-14, 2021. The presentation will be available on-demand starting at 6:00 a.m. ET on January 11 and can be accessed via the conference portal and OptimizeRx’s investor relations page. CEO William Febbo will hold one-on-one virtual meetings with institutional analysts and investors, highlighting the company's expanding market due to new digital health solutions. OptimizeRx reported $34.3 million in trailing revenue for the 12 months ending September 30, 2020, marking a 44% increase from the previous year.
Summary not available.
OptimizeRx Corp. (Nasdaq: OPRX) has been invited to the Bank of America 4th Annual HCIT and Digital Health Symposium on December 9-10, 2020. CEO William Febbo will speak on the panel discussing "Trends in Tech-Enabled Rx Supply Chain." The event will include healthcare-focused Bank of America clients and executives from various sectors, including digital health and private equity. OptimizeRx offers digital health solutions linking healthcare providers and patients, helping improve medication affordability and adherence.
OptimizeRx announces a partnership with Komodo Health to integrate its Healthcare Map with OptimizeRx's digital health platform. This collaboration aims to enhance real-world evidence delivery to healthcare providers, expanding OptimizeRx's audience and improving care through actionable insights. As the COVID-19 pandemic has changed care delivery, the partnership focuses on addressing gaps in timely information for healthcare providers. OptimizeRx aims to leverage this integration to bolster patient and physician experiences, ultimately improving treatment outcomes.
OptimizeRx Corp. (Nasdaq: OPRX) has launched an innovative enhancement to its digital health platform that utilizes real-world data (RWD) and machine learning to deliver therapeutic support directly to clinicians at critical patient care moments. This unprecedented approach aims to improve communication and data accessibility in healthcare, potentially enhancing patient outcomes, especially in complex cases like oncology. OptimizeRx emphasizes the importance of actionable data for effective treatment decisions and aims to improve healthcare systems through its AI-driven capabilities.
OptimizeRx Corp. (Nasdaq: OPRX) has reported a remarkable 217% revenue growth from 2016 to 2019, attributed to its expanding digital health platform. The company earned the 432nd spot on Deloitte’s Technology Fast 500, recognizing fast-growing tech companies in North America. CEO William Febbo emphasized the significance of their digital health solutions and a dedicated team. The recent record revenue of $10.5 million for Q3 2020, reflecting a 110% increase year-over-year, signals continued strong performance in a growing market.
OptimizeRx Corp. (Nasdaq: OPRX) has partnered with Fierce Life Sciences to host a virtual event, Innovate4Outcomes, on December 3, 2020. The event aims to address key healthcare challenges exacerbated by COVID-19, promoting collaboration among industry leaders to enhance patient outcomes. Discussions will focus on supporting providers, the role of clinicians in digital strategies, adoption of patient support programs, and leveraging social media for patient engagement. Attendance is limited to 100 participants.
OptimizeRx Corp. (Nasdaq: OPRX) has appointed Angelo Campano as senior vice president and principal of agency channels to enhance partnerships with healthcare advertising agencies. With over 15 years of experience, Campano aims to drive strategic growth at OptimizeRx, including implementing point-of-care engagement programs for targeted patient populations. His background includes significant achievements in electronic health record (EHR) workflows and marketing at Ogilvy Health. The company's digital health platform connects life sciences with healthcare providers, facilitating medication affordability for patients.